Structure Therapeutics’ Oral GLP-1 Aleniglipron Achieves 16.3% Weight Reduction in Phase 2, Advances to Phase 3 Amidst Robust Obesity Pipeline

September 6, 2026

Becker’s Hospital Review Unknown

Overview

A pipeline update on 13 experimental weight-loss drugs highlights Structure Therapeutics’ oral GLP-1 agent, Aleniglipron, which demonstrated a remarkable 16.3% placebo-adjusted weight reduction in its Phase 2 trial and is now advancing to Phase 3. Separately, Novo Nordisk’s oral and injectable dual GLP-1/amylin agonists and Eli Lilly’s triple agonist Retatrutide reported promising results in Phase 2 and Phase 3, respectively, showcasing significant weight loss. These advancements indicate a strong emergence of oral and multi-agonist therapies in the obesity treatment market.

In Depth

Key Findings

Significant progress has been reported in the obesity therapeutic pipeline, with Structure Therapeutics’ oral GLP-1 drug, Aleniglipron, achieving a notable 16.3% placebo-adjusted weight reduction in its Phase 2 clinical trial, securing its progression to Phase 3. This marks a critical milestone in the development of innovative, orally administered treatments for obesity.

Technical / Clinical Details

Aleniglipron’s Efficacy: Structure Therapeutics’ Aleniglipron is an orally administered GLP-1 receptor agonist, a key differentiator in a market predominantly featuring injectables. In its Phase 2 study, participants experienced an average of 16.3% weight loss compared to the placebo group. This figure is comparable to, or even exceeds, the efficacy observed with some existing injectable GLP-1 receptor agonists, underscoring its high potential as an oral agent.
Novo Nordisk’s Dual Agonists: Novo Nordisk is developing dual agonists targeting both GLP-1 and amylin receptors, available in both oral and injectable forms. Phase 2 trials for these agents have also demonstrated promising weight loss benefits, with expectations of superior efficacy compared to GLP-1 monotherapy. Amylin contributes to weight management through mechanisms such as delayed gastric emptying, enhanced satiety, and suppression of glucagon secretion.
Eli Lilly’s Retatrutide: Eli Lilly’s Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, has reported exceptionally high weight loss efficacy in its Phase 2 and Phase 3 trials. Previous reports indicate weight reductions exceeding 24% in some cohorts, positioning it among the most potent obesity medications currently under development.

Background & Context

Obesity represents a growing global public health crisis, contributing to a myriad of serious comorbidities including cardiovascular disease, diabetes, and certain cancers. While GLP-1 receptor agonists have shown revolutionary effects in weight reduction and metabolic improvement, many patients are reluctant to use injectable formulations. Consequently, the development of orally administered GLP-1-related agonists addresses a significant unmet need in the market.

Multi-agonist therapies are anticipated to offer superior efficacy by acting on multiple physiological pathways simultaneously, potentially transforming the standard of care for obesity.

Strategic Significance & Outlook

Aleniglipron’s advancement to Phase 3 suggests that oral GLP-1 drugs could rival the efficacy of injectables, intensifying competition in the obesity treatment market. Coupled with the progress of Novo Nordisk and Eli Lilly’s multi-agonists, the range of obesity treatment options is projected to dramatically expand in the coming years, enabling more personalized therapeutic strategies. This is expected to lead to improved weight management and reduced associated diseases for a broad patient population, delivering substantial public health benefits.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.